Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Leukemia
CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
A durable complete response was achieved in a high proportion of adults with refractory B-cell malignancies who received CD19+ chimeric antigen receptor (CAR) T-cells made up of a defined 1:1 ratio of CD8+ and CD4+ cells.
Read Article
Immunotherapy with Blinatumomab Prolongs Survival in Acute Lymphoblastic Leukemia
By
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Treatment with CD19-targeted immunotherapy blinatumomab (Blincyto) as a single agent showed antileukemic activity in patients with minimal residual disease (MRD) Philadelphia chromosome (Ph)-positive B-cell precursor acute lymphoblastic leukemia (ALL) whose disease progressed after or was intolerant to a second-generation or later tyrosine kinase inhibitor (TKI). The results were presented at ASH 2015.
Read Article
Ibrutinib a New Standard of Care for Elderly Patients with Chronic Lymphocytic Leukemia
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Ibrutinib (Imbruvica) significantly reduced the risk for disease progression or death compared with standard treatment with chlorambucil (Leukeran) in older (aged ≥65 years) treatment-naive patients with chronic lymphocytic leukemia (CLL). Ibrutinib achieved a 91% reduction in the risk for disease progression and an 84% reduction in the risk for death compared with chlorambucil.
Read Article
Idelalisib Improves Survival When Added to Bendamustine plus Rituximab in Patients with CLL
By
Phoebe Starr
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Idelalisib (Zydelig) reduced the risk for disease progression and death when added to bendamustine (Treanda) plus rituximab (Rituxan) versus bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of a randomized, double-blind, placebo-controlled, phase 3 late-breaking trial presented at ASH 2015.
Read Article
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
By
Chase Doyle
Hematologic Malignancies
,
Leukemia
February 2016, Vol 7, No 1
Dose-optimized nilotinib (Tasigna) increased the rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP) in the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Extending Molecular Responses (ENESTxtnd) study. According to the final results of this study presented at ASH 2015, the cumulative major molecular response rates were 70.8% by 12 months and 81.0% by 24 months in patients managed with the dose optimization strategy.
Read Article
Rituximab Boosts Chemotherapy Benefit in Patients with B-Cell Precursor ALL
By
Dana Taylor
Hematologic Malignancies
,
Leukemia
March 2016, Vol 7, No 2
In patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the addition of rituximab (Rituxan) to chemotherapy significantly improved event-free survival in a large European study.
Read Article
Monitoring Response to TKI Therapy by PCR Improves Outcomes in Chronic Myeloid Leukemia
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
March 2015, Vol 6, No 2
Disease progression is slower and overall survival (OS) is greater in patients with chronic myeloid leukemia (CML) who are being monitored for their response to tyrosine kinase inhibitor (TKI) therapy and show good adherence. However, few clinicians monitor response and adherence to oral TKI treatment in patients with CML.
Read Article
Vosaroxin, a Quinolone Derivative, Extends Survival in Older Patients with Acute Myeloid Leukemia
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
March 2015, Vol 6, No 2
An investigational first-in-class anticancer quinolone derivative, vosaroxin, extended median overall survival (OS) when used with cytarabine (Cytosar-U) in a phase 3 clinical trial of patients with relapsed or refractory acute myeloid leukemia (AML), although the difference was not significant.
Read Article
Blinatumomab Immunotherapy Attacks Minimal Residual Disease in ALL, Leads to High Rates of Complete Response
By
Wayne Kuznar
Hematologic Malignancies
,
Leukemia
March 2015, Vol 6, No 2
San Francisco, CA—In patients with acute lymphoblastic leukemia (ALL), assessment of minimal residual disease (MRD) is increasingly used to evaluate response to treatment. An antibody that recruits the body’s T-cells to attack MRD in patients with ALL whose disease is in remission can prevent full relapse.
Read Article
Novel CAR-T Therapy Shows Impressive Results in Aggressive Leukemia, Lymphoma
By
Phoebe Starr
Leukemia
,
Lymphoma
,
Personalized Medicine
February 2014, Vol 5, No 1
New Orleans, LA—Mounting evidence from several research centers shows that autologous T-cells genetically engineered with a chimeric antigen receptor-T (CAR-T; also called CTL019) achieve dramatic responses in patients with advanced leukemia and lymphoma who have exhausted all treatment options.
Read Article
Page 7 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma